Program
elebsiran
Also written as “VIR-2218”, “Elebsiran” and “BRII-835 (VIR-2218)”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Renal Insufficiency · Fibrosis · Hepatitis D, Chronic, led by 3 companies.
Drug pageElebsiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vir Biotechnology | 84 open or running | phase 3since Mar 24, 2025 | Sep 11, 2018 | Dec 2026phase 3 · NCT07128550 |
| Brii Biosciencesits history only | 20 open or running | phase 2since Aug 7, 2020 | Aug 7, 2020 | none ahead |
| Virion Therapeuticsits history only | 10 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
Also a collaborator on its studies: VBI Vaccines and Alnylam Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Vir Biotechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 11, 2018First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT03672188 · 82 enrolled · Australia, Hong Kong, Korea, Republic of and more
- May 29, 2020Phase 2 study in Hepatitis B, ChronicNCT04412863 · 84 enrolled · Australia, Hong Kong, Malaysia and more
- Jul 1, 2022Phase 2 study in Hepatitis D, ChronicNCT05461170 · 95 enrolled · Bulgaria, France, Germany and more
- Jul 15, 2022Phase 1 study in FibrosisNCT05484206 · 88 enrolled · United States
- Jul 21, 2022Named elebsiranINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-2218
- Apr 24, 2023Phase 1 study in Renal InsufficiencyNCT05844228 · 28 enrolled · United States
- Mar 24, 2025Phase 3 study in HepatitisNCT06903338 · 124 enrolled · United States, Canada, Georgia and more
- Aug 13, 2025Phase 3 study in HepatitisNCT07128550 · 150 enrolled · Austria, France, Germany and more
- Aug 19, 2025Phase 2 study in HepatitisNCT07142811 · 100 enrolled · Belgium, Bulgaria, France and more
- Nov 17, 2026Primary completion moved from 2026-11 to 2029-03Date moved laterphase 2 · +28 months · NCT07142811
Ahead
- Dec 2026Primary completion: phase 3 study in HepatitisNCT07128550
- Mar 2029Primary completion: phase 2 study in HepatitisNCT07142811
- Nov 2031Primary completion: phase 2 study in Hepatitis D, ChronicNCT05461170
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 Vir Biotechnology leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07142811Hepatitis · Belgium, Bulgaria, France and more | 2 | Active, not recruiting | Mar 2029 | 100 |
| NCT07128550Hepatitis · Austria, France, Germany and more | 3 | Active, not recruiting | Dec 2026 | 150 |
| NCT06903338Hepatitis · United States, Canada, Georgia and more | 3 | Active, not recruiting | Sep 30, 2026 | 124 |
| NCT05844228Renal Insufficiency · United States | 1 | Completed | Mar 1, 2025 | 28 |
| NCT05484206Fibrosis · United States | 1 | Completed | Dec 9, 2025 | 88 |
| NCT05461170Hepatitis D, Chronic · Bulgaria, France, Germany and more | 2 | Active, not recruiting | Nov 2031 | 95 |
| NCT04412863Hepatitis B, Chronic · Australia, Hong Kong, Malaysia and more | 2 | Completed | Mar 25, 2024 | 84 |
| NCT03672188Hepatitis B, Chronic · Australia, Hong Kong, Korea, Republic of and more | 2 | Completed | Sep 3, 2020 | 82 |
How it is read
Names in the registry
- “VIR-2218”, 7 entries
- “Elebsiran”, 3 entries
- “BRII-835 (VIR-2218)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 5 studies
- Hepatitis, 3 studies
- Renal Insufficiency, 1 study
- Fibrosis, 1 study
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.